Cargando…
The in vivo Anti‐tumor Effect of Human Recombinant Interleukin‐6
Administration of recombinant interleukin‐6 (IL‐6) was found to induce in vivo generation of cytotoxic T lymphocytes (CTL) against syngeneic transplantable erythroleukemia (FBL‐3) in lymph node cells and peritoneal exudate cells (PEC) in C57BL/6 mice. Furthermore, 15 out of 16 C57BL/6 mice injected...
Autores principales: | Kitahara, Misa, Kishimoto, Susumu, Hirano, Toshio, Kishimoto, Tadamitsu, Okada, Masaji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917969/ https://www.ncbi.nlm.nih.gov/pubmed/2121676 http://dx.doi.org/10.1111/j.1349-7006.1990.tb03342.x |
Ejemplares similares
-
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
por: Tanaka, Toshio, et al.
Publicado: (2012) -
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Mihara, Masahiko, et al.
Publicado: (2011) -
Interleukin-6: discovery of a pleiotropic cytokine
por: Kishimoto, Tadamitsu
Publicado: (2006) -
Soluble Interleukin‐6 Receptor Is Released from Receptor‐bearing Cell Lines in vitro
por: Nakajima, Toshiharu, et al.
Publicado: (1992) -
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
por: Kang, Sujin, et al.
Publicado: (2021)